Novartis AG ADR (NVS)vsRapid Micro Biosystems Inc (RPID)
NVS
Novartis AG ADR
$162.55
+0.38%
HEALTHCARE · Cap: $303.67B
RPID
Rapid Micro Biosystems Inc
$0.64
+3.42%
HEALTHCARE · Cap: $39.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 162977% more annual revenue ($57.36B vs $35.18M). NVS leads profitability with a 17.5% profit margin vs -145.6%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
RPID
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$162.55
$66.99 premium
Intrinsic value data unavailable for RPID.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : RPID
The strongest argument for RPID centers on Price/Book. Revenue growth of 10.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while RPID is a turnaround play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.50 — expect wider price swings.
RPID is growing revenue faster at 10.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 30/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology firm at the forefront of revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, addressing the stringent regulatory requirements within these sectors. As the demand for rapid quality assurance solutions continues to grow, Rapid Micro is well-positioned to spearhead advancements in testing methodologies, ensuring product safety and integrity in highly regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?